News about Global Pharma

Emcure Pharma Taps Industry Veteran R.S. Vasan to Lead India Business

Emcure Pharmaceuticals Ltd. has appointed R.S. Vasan as President – India Business and Senior Management Personnel (SMP).

Global Pharma | 16/07/2025 | By Dineshwori |  628

MPP-ViiV Agreement Expanded: Aurobindo, Cipla and Viatris to Make Generic HIV Drug Cabotegravir

ViiV Healthcare and the Medicines Patent Pool (MPP) have expanded their voluntary licensing agreement for cabotegravir, enabling manufacturers such as Aurobindo, Cipla, and Viatris to develop, manufacture, and supply generic versions for the HIV treatment in 133 countries.

Global Pharma | 15/07/2025 | By Dineshwori |  739

Jubilant Ingrevia Appoints Kailash Ukhade as Vice President - Projects

Jubilant Ingrevia Ltd. has announced the appointment of Kailash Ukhade as Vice President – Projects, based in Bharuch.

Global Pharma | 15/07/2025 | By Dineshwori |  309

Evonik Opens New Medical Device Application Center in Shanghai to Serve Asian Market

The Evonik Shanghai Medical Device Center is designed to help manufacturers tackle complex challenges and accelerate innovation in medical technologies.

Global Pharma | 14/07/2025 | By Dineshwori |  400

Senores Pharmaceuticals Inks SPA to Raise Stake in Havix

Senores Pharmaceuticals Ltd. (SPL) has entered into a Share Purchase Agreement (SPA) with a public shareholder of Havix Group Inc., doing business as Aavis Pharmaceuticals (Havix), to acquire 6,730 equity shares — representing 2.97 percent of Havix’s total paid-up share capital.

Global Pharma | 14/07/2025 | By Dineshwori |  517

Cipla to Enter Weight Management Segment, Expands Focus on Oncology and CNS Therapies

Cipla is set to enter India’s growing weight management market as part of its broader strategy to expand across emerging therapeutic segments.

Global Pharma | 14/07/2025 | By Dineshwori |  296

Wockhardt Realigns US Operations to Focus on Innovative Portfolio, Exits Generic Pharma Segment

Wockhardt has announced a strategic realignment of its US operations, exiting the loss-making generics business to focus on its innovation-led priorities in novel antibiotics and biologics, marking a decisive shift toward building a differentiated, future-ready pharmaceutical enterprise.

Global Pharma | 11/07/2025 | By Mrinmoy Dey |  745

Novartis Signs Brain Delivery Deal With Sironax, Wraps pCPA Talks on Cosentyx Reimbursement

Novartis has signed an exclusive option agreement with Chinese biotech firm Sironax to potentially acquire its proprietary Brain Delivery Module (BDM) platform and concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on the public reimbursement of Cosentyx.

Global Pharma | 11/07/2025 | By Dineshwori |  381

Glenmark's IGI Signs Licensing Deal with AbbVie for Investigational Cancer Therapy

AbbVie to lead global development, manufacturing and commercialisation of Ichnos Glenmark Innovation’s (IGI) investigational cancer therapy ISB 2001 in North America, Europe, Japan, and Greater China, while Glenmark will take these roles in emerging markets.

Global Pharma | 11/07/2025 | By Dineshwori |  376

Celltrion Announces Three-Stage Strategy to Counter Trump's Pharma Tariff Plan

Celltrion has announced its response strategy to US President Donald Trump’s plan to impose tariffs on pharmaceuticals.

Global Pharma | 10/07/2025 | By Dineshwori |  577